Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Objective: The objective of our study was to investigate the comparative effectiveness of antipsychotics for the risk of attempted or completed suicide among all patients with schizophrenia in Finland and Sweden. Methods: Two nationwide register-based cohort studies were conducted, including all individuals with schizophrenia in Finland (n = 61 889) and Sweden (n=29 823). The main exposure was 10 most commonly used antipsychotic monotherapies; also, adjunctive pharmacotherapies were investigated. The main outcome measure was attempted or completed suicide, which was analyzed with within-individual models by comparing use and nonuse periods in the same individual to minimize selection bias. Sensitivity analyses included attempted suicide (hospitalization only) as an outcome. Results: Compared with no use of antipsychotics, clozapine use was the only antipsychotic consistently associated with a decreased risk of suicidal outcomes. Hazard ratios (HRs) and 95% CIs for attempted or completed suicide were 0.64 (0.49–0.84) in the Finnish cohort and 0.66 (0.43–0.99) in the Swedish cohort. No other antipsychotic was associated with a reduced risk of attempted and/or completed suicide. Benzodiazepines and Z-drugs were associated with an increased risk of attempted or completed suicide (HRs: 1.29–1.30 for benzodiazepines and 1.33–1.62 for Z-drugs). Conclusion: Clozapine was the only antipsychotic associated with decreased risk of attempted or completed suicide among patients with schizophrenia, and it should be considered as first-line treatment for high-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with clozapine has also been associated with decreased risk of suicide in adults with psychotic disorders, 142 but comparable studies in young people are lacking.”
From Suicide in young people: screening, risk assessment, and intervention (2023) · cites this paper as [142]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Self-citationLithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013) · BMJ · doi:10.1136/bmj.f3646 · Cited by 920
Review: Suicide and schizophrenia: a systematic review of rates and risk factors
Hor, K., & Taylor, M. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810385490 · Cited by 853
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670
Self-citationMedication for Attention Deficit–Hyperactivity Disorder and Criminality
Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjölander, A., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203241 · Cited by 611
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Tanskanen, A., & Haukka, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.12.1358 · Cited by 277
Self-citationPolypharmacy With Antipsychotics, Antidepressants, or Benzodiazepines and Mortality in Schizophrenia
Tiihonen, J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1532 · Cited by 253
Self-citationClinical pharmacology of atypical antipsychotics: an update
Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014) · Technische Universität Dortmund · doi:10.17877/de290r-7037 · Cited by 250
Research works printed but not linked: 1
- 29. Kraus JE, Sheitman BB. Clozapine reduces violent behavior in groups. J Neuropsychiatr. 2005;17(1):36-44. · doi:10.1176/jnp.17.1.36
Cited by
Suicide in young people: screening, risk assessment, and intervention
Hughes, J. L., Horowitz, L. M., Ackerman, J. P., Adrian, M. C., Campo, J. V., & Bridge, J. A. (2023) · BMJ · doi:10.1136/bmj-2022-070630 · Cited by 135
The Lancet Commission on self-harm
Moran, P., Chandler, A., Dudgeon, P., Kirtley, O. J., Knipe, D. W., Pirkis, J., Sinyor, M., Allister, R., Ansloos, J. P., Ball, M. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01121-8 · Cited by 160
Prevention of suicide by clozapine in mental disorders: systematic review
Masdrakis, V. G., & Baldwin, D. S. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.12.011 · Cited by 103
“Additionally, it dramatically and chronically increases peripheral norepinephrine levels ( Green et al., 1993 ; Taipale et al., 2021 ).”
Influentialde Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., Luca, V. D., Iasevoli, F., & Correll, C. U. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108236 · Cited by 98
Huang, C.-Y., Fang, S., & Shao, Y. J. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8810 · Cited by 70
Pardiñas, A. F., Kappel, D. B., Roberts, M., Tipple, F., Shitomi-Jones, L. M., King, A., Jansen, J., Helthuis, M., Owen, M. J., O’Donovan, M. C., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00002-0 · Cited by 60
A Neurodevelopment Approach for a Transitional Model of Early Onset Schizophrenia
Berardis, D. D., Filippis, S. D., Masi, G., Vicari, S., & Zuddas, A. (2021) · Brain Sciences · doi:10.3390/brainsci11020275 · Cited by 63
Tiihonen, J., Tanskanen, A., Bell, J. S., Dawson, J. L., Kataja, V., & Taipale, H. T. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00044-x · Cited by 49
Self-citationThe Importance of Suicide Risk Formulation in Schizophrenia
Berardelli, I., Rogante, E., Sarubbi, S., Erbuto, D., Lester, D., & Pompili, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.779684 · Cited by 57
“(170) investigated the risk of attempted and completed suicide in patients with schizophrenia.”
Backgroundde León, J., Baldessarini, R. J., Balon, R., Bilbily, J., Caroff, S. N., Citrome, L., Correll, C. U., Cotes, R. O., Davis, J. M., DeLisi, L. E., et al. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001990 · Cited by 39
de León, J., Baldessarini, R. J., Balon, R., Bilbily, J., Caroff, S. N., Citrome, L., Correll, C. U., Cotes, R. O., Davis, J. M., DeLisi, L. E., et al. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001987 · Cited by 40
Chen, W., Chen, P., Pan, C., Su, S., Tsai, S., Chen, C.-C., & Kuo, C. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.07.014 · Cited by 32
Cuevas, C. D. L., de León-Martínez, V., Blasco-Fontecilla, H., Baca‐García, E., Šagud, M., Sanz, E. J., & de León, J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2399094 · Cited by 28
Verdoux, H., Quilès, C., & de León, J. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.03.032 · Cited by 29
Miller, B. J., & McCall, W. V. (2021) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.9646 · Cited by 24
“2 A large Danish incidence cohort of patients with nonaffective psychosis also found significantly decreased risk of suicide death during current use of clozapine.”
Izsák, B., Hidvégi, A., Bálint, L., Málnási, T., Vargha, M., Pándics, T., Rihmer, Z., & Döme, P. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.11.041 · Cited by 26
“Besides clozapine (which is FDA-approved for suicide prevention in subjects with schizophrenia), lithium is the only medication with strongly proven suicide-preventive features (Barroilhet and Ghaemi, 2020; Gitlin, 2020; Hidv ´ egi et al., 2016; McIntyre et al., 2020; Taipale et al., 2021).”
Botchway, S., Tsiachristas, A., Pollard, J., & Fazel, S. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.2354 · Cited by 22
“The effects on suicide risk following HRM were based primarily on trial evidence such as RCTs showing reduced odds of suicide in SMI patients taking lithium and antipsychotics [7, 22] but other treatments were considered.”
BackgroundXie, W.-L., Xiang, D.-C., Li, Y., Ge, M.-L., & Deng, A. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00858-7 · Cited by 21
Cuevas, C. D. L., Sanz, E. J., Tezanos, A. G. V., & de León, J. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2192401 · Cited by 18
“The low number of respiratory aspirations in clozapine patients may also be confounded by the anti-suicidal effect of clozapine [62,63].”
BackgroundTaipale, H. T., Lieslehto, J., Lähteenvuo, M., Hamina, A., Tanskanen, A., Mittendorfer‐Rutz, E., Paljärvi, T., Solmi, M., Cipriani, A., Correll, C. U., et al. (2024) · World Psychiatry · doi:10.1002/wps.21205 · Cited by 17
“These preparations have been associated with better treatment outcomes than oral antipsychotics in several real-world studies of schizophrenia and bipolar disorder 14,15,29 .”
BackgroundSelf-citationGlial Markers of Suicidal Behavior in the Human Brain—A Systematic Review of Postmortem Studies
Yamamoto, M., Sakai, M., Yu, Z., Nakanishi, M., & Yoshii, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115750 · Cited by 19
“Another study also confirmed increased transcription of TJP1/ZO-1 and CTNNA1 in the dACC of suicidal patients with depression compared to psychiatrically normal controls [56].”
ResultCuevas, C. D. L., Sanz, E. J., Jiménez‐Fernández, S., Schoretsanitis, G., Ruan, C., & de León, J. (2024) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-024-02623-3 · Cited by 18
“Supplementary Box S1 [5, 9, 15, 19–23] provides a detailed description of the complexity of clozapine pharmacovigilance in VigiBase in general and regarding suicide.”
Samara, M. T., Lappas, A. S., Pinioti, E., Glarou, E., Fober, I., Christogiannis, C., Siafis, S., Christodoulou, G. N., Helfer, B., Mavridis, D., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103291 · Cited by 18
Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia
Lee, M. A., Cola, P. A., Jayathilake, K., & Meltzer, H. Y. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001671 · Cited by 18
Anti-Suicidal Effects of Lithium, Ketamine, and Clozapine—A 10-Year Systematic Review
Waszak, P. M., Opalko, J., Olszańska, N., & Zagożdżon, P. (2025) · Pharmaceuticals · doi:10.3390/ph18050742 · Cited by 15
“Conversely, benzodiazepines and Z-drugs were linked to an increased risk, with HRs ranging from 1.29 to 1.62 [66] Van der Zalm et al. analyzed mortality among 22,110 Danish patients with first-time nonaffective psychotic disorders and a broader cohort of 50,881 individuals with prior diagnoses.”
InfluentialStrømme, M. F., Augustsson, M. T., Bartz-Johannessen, C. A., Stautland, A., Mykletun, A., Kroken, R. A., Mehlum, L. I., Kjelby, E., & Johnsen, E. (2024) · Psychological Medicine · doi:10.1017/s0033291724002873 · Cited by 11
Tuominen, L. J., Armio, R.-L., Hansen, J. Y., Walta, M., Koutsouleris, N., Laurikainen, H., Salokangas, R. K. R., Mišić, B., & Hietala, J. A. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03336-0 · Cited by 13
Effect of clozapine on suicidality in patients with schizophrenia at a university hospital in Turkey
Gürcan, G., Şenol, Ş. H., Yağcioğlu, A. E. A., & Ertuğrul, A. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.08.029 · Cited by 9
Pediatric suicide: Review of a preventable tragedy
Greydanus, D. E., Nazeer, A., Qayyum, Z., Patel, D. R., Rausch, R., Hoang, L.-N., Miller, C., Chahin, S. S., Apple, R. W., Saha, G. K., et al. (2024) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101725 · Cited by 13
Fang, C. Z., Chan, J. K. N., Solmi, M., Wong, C. S. M., Lui, S. S. Y., Correll, C. U., & Chang, W. C. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.05.003 · Cited by 9
Wong, S., Meckling, G., Fabiano, N., Lee, S., Jones, B. D. M., Shorr, R., Dargél, A., Davis, A. K., Fiedorowicz, J. G., Solmi, M., et al. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251372449 · Cited by 10
“15 Lithium is believed to reduce impulsive and aggressive behavior that may lead to increased SI and SA.”
InfluentialClozapine and Suicide in VigiBase
de León, J., de León-Martínez, V., Sanz, E. J., & Cuevas, C. D. L. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002111 · Cited by 8
Herttua, K., Crawford, M., Paljärvi, T., & Fazel, S. (2022) · Evidence-Based Mental Health · doi:10.1136/ebmental-2022-300493 · Cited by 12
Improved insomnia is one pathway underlying the anti‐suicidal properties of clozapine
Vayalapalli, A., McCall, W. V., McEvoy, J. P., & Miller, B. J. (2024) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.13099 · Cited by 8
Taipale, H. T., Siskind, D. J., Tanskanen, A. J., Mittendorfer‐Rutz, E., Correll, C. U., & Tiihonen, J. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00163-4 · Cited by 9
Self-citationBaird, A., Rathod, S., Hansen, L. K., Appleby, L., Rodway, C., & Turnbull, P. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf009 · Cited by 8
Min, S., Yeum, T.-S., Shin, D., Rhee, S. J., Lee, H., Lee, H.-S., Park, S., Lee, J., & Ahn, Y. M. (2025) · JMIR Medical Informatics · doi:10.2196/79093 · Cited by 12
Kozhevnikova, S., Emilian, C. A., Scola, G., Chang, Z., Yukhnenko, D., & Fazel, S. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103800 · Cited by 11
Bossarte, R. M., Kennedy, C. J., Luedtke, A. R., Nock, M. K., Smoller, J. W., Stokes, C. M., & Kessler, R. C. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab111 · Cited by 7
“Medication codes collapsed across therapeutic classes can be refined to distinguish medications within classes that protect against SRBs, such as lithium for bipolar disorder (27) and clozapine for schizophrenia (28) and to distinguish medications with suicide risk warnings or that pharmacoepidemiologic studies find p…”
BackgroundClozapine, Long-Acting Injectables (and Polypharmacy?) Superior in U.S. and International Registries
Leucht, S., & Tiihonen, J. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21080825 · Cited by 7
Self-citationMäkipelto, V., Tuulio‐Henriksson, A., Hakulinen, C. A., Niemelä, S., Lähteenvuo, M., Wegelius, A., Kieseppä, T., Isometsä, E. T., Tiihonen, J., Kampman, O., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.02.025 · Cited by 6
“A causal explanation would be in line with earlier research demonstrating an association between benzodiazepine use and other adverse outcomes (Fontanella et al., 2016; Taipale et al., 2021).”
Self-citationYang, J. H., Park, C. H. K., Rhee, S. J., Kang, D. H., Kim, M. J., Lee, H. J., Lee, S.-Y., Shim, S.-H., Moon, J., Cho, S., et al. (2024) · Journal of Korean Medical Science · doi:10.3346/jkms.2024.39.e226 · Cited by 8
Zhou, H., Luo, H., Tang, J. Y. ‐., Honer, W. G., Bastiampillai, T. J., Zhou, J., Taipale, H. T., Chang, W. C., Lui, S. S. Y., Lee, E. H. M., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.10312 · Cited by 10
“16,30 The superior efficacy of clozapine in alleviating psychotic symptoms and depressive symptoms 31,32 and its efficacy in controlling aggressive and impulsive behaviour 32 might also contribute to its effects in reducing suicide and death.”
Self-citationMénard, M.-L., Auby, P., Cruzel, C., Cohen, D., Bonnot, O., Askenazy-Gittard, F., Thümmler, S., ETAPE Study Group, Michel, B., Agnès, C., et al. (2022) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-022-00517-3 · Cited by 5
“What we know today, among the APs, clozapine was the only AP which has been associated with decreased risk of attempted or completed suicide in the Swedish cohort included all persons aged 16–64 with schizophrenia diagnoses [37, 38].”
Schizophrenia: advances in pathophysiology, management, and precision medicine
Sawa, A., Chiappelli, J., Hamrah, O., & Cascella, N. G. (2026) · BMJ · doi:10.1136/bmj-2026-635470 · Cited by 4
“…A study of two nationwide cohorts including >90 000 patients found that clozapine was the only antipsychotic associated with a significantly lower risk of attempted or completed suicide compared with no medication (hazard ratio 0.64 and 0.66), 115 previously found in a multisite randomised trial.”
InfluentialKorkmaz, Ş. A., Koca, E., Yilmaz, Ö., Özbek, T., Güçlü, M. A., & Kızgın, S. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001837 · Cited by 6
de Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., Luca, V. D., Iasevoli, F., & Correll, C. U. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4089530 · Cited by 4
Scheinberg, R., Fu, Z., Scott, L., Baker, K. K., Cuerdo, A., Zhong, L., Bethany, C., Harper, M., Nucifora, L. G., Brandt, A. S., et al. (2025) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaf009 · Cited by 4
Yin, Y., Chen, L., Wei, L., Tong, J., Huang, J., Tian, B., Tan, S., Wang, Z., Yang, F., Tong, Y., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05893-y · Cited by 3
“In fact, clozapine is underutilized in many countries [32], although research suggests that clozapine reduces self-harm [7–9] and mortality compared with other antipsychotics [10, 33].”
Backgroundde León, J., Šagud, M., Sanz, E. J., & Cuevas, C. D. L. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116408 · Cited by 3
Diabetes mellitus prevalence in Northland New Zealand schizophrenia patients on clozapine
Abraham, A. C., McGrath, N. M., & Humberstone, V. (2022) · New Zealand Medical Journal · doi:10.26635/6965.5688 · Cited by 3
An Update on Somatic Treatments for Suicide Risk
Rizk, M., & Mann, J. J. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260287 · Cited by 4
Zarzar, T. R., Rosen, D. L., Mayo, J. P., O'Connell, M. G., Catlett, T. L., Reed, J., Williams, J. B., & Sheitman, B. (2022) · Journal of Correctional Health Care · doi:10.1089/jchc.21.02.0014 · Cited by 2
“Despite its added side effects, clozapine has been shown in multiple studies to have a lower all-cause mortality rate compared with other antipsychotic drugs, driven largely by its effect on suicidal behavior (Taipale et al. , 2021; Tiihonen et al. , 2009; Wimberley et al. , 2017).”
The clean and dirty ways to reduce suicidality
Sivolap, Y. P., & Portnova, A. A. (2021) · Neurology Bulletin · doi:10.17816/nb71327 · Cited by 1
Suicide and psychiatric disorders
Berardelli, I., Rogante, E., Lamis, D. A., & Pompili, M. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780198843405.003.0018 · Cited by 2
Second-Generation Antipsychotics and Real-World Outcomes in Youth With On- and Off-Label Indications
Zhang, L., Quinn, P. D., Bjureberg, J., Hellner, C., Sepe-Forrest, L., Brikell, I., Kuja‐Halkola, R., Froehlich, T. E., D'Onofrio, B. M., & Chang, Z. (2026) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2026.01.009 · Cited by 2
Kaster, T. S., Rhee, T. G., Adler, E., & Kirov, G. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10613 · Cited by 3
“6 Because clinical trials cannot capture rare or long-term outcomes, or may not reflect typical patients receiving treatment, important gaps remain in understanding the risks and benefits of ECT.”
Dhaliwal, N., Kaladharan, S., Waldmann, J., Siskind, D. J., & Parker, S. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002198 · Cited by 1
Luo, N., Xiao, L., Liu, Y., & Liu, X. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71217 · Cited by 1
“…limit of the 95% CI of EBGM; IC, information component; IC025, the lower limit of the 95% CI of the IC; PRR, proportional reporting ratio; PT, preferred term; ROR, reporting odds ratio. a For adverse events not documented in the instructions. of the short study periods and small sample sizes [42].”
Variations in Secondary Health Resource Utilization Post Clozapine Initiation
de Silva, P. N. (2020) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2004078 · Cited by 1
Suicide Risk Among Psychiatric Patients
Isometsä, E. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-42003-1_28 · Cited by 1
The Narrative-Crisis Model of Suicide as a Framework for Suicide Prevention
Goncearenco, I., Chennapragada, L., & Rogers, M. L. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197582718.003.0010 · Cited by 3
Оценка суицидального риска: новые решения «проклятых вопросов»
Любов, Е. Б., & Zotov, P. B. (2023) · Суицидология · doi:10.32878/suiciderus.23-14-02(51)-22-35 · Cited by 1
“Safe environments, pharmacotherapy (especially clozapine for schizophrenia) and/or psychotherapy (like CBT) can and should reduce SB in the high-risk SMD group [71, 76].”
Refractory pain in a schizophrenic patient on clozapine
Asiimwe, E., DeFraites, E., & Feher, C. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-246574 · Cited by 1
Progress in Schizophrenia Research and Treatment
(2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18310 · Cited by 1
Te, T. T. (2021) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.9826
P.0457 Effect of clozapine on suicidality in patients with schizophrenia
Gürcan, G., Şenol, Ş. H., Yağcioğlu, A. E. A., & Ertuğrul, A. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.430
Suicide Risk Among Psychiatric Patients
Isometsä, E. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-41319-4_28-1 · Cited by 1
Ménard, M.-L., Auby, P., Cruzel, C., Cohen, D., Bonnot, O., Askenazy-Gittard, F., Thümmler, S., & ETAPE Study group (2022) · Research Square · doi:10.21203/rs.3.rs-1894098/v1
Krauss, A., Bernard, J. D., & Okusaga, O. O. (2022) · Federal Practitioner · doi:10.12788/fp.0338 · Cited by 3
Korkmaz, Ş. A., Koca, E., Yılmaz, Ö., Özbek, T., & Güçlü, M. A. (2023) · doi:10.22541/au.169336444.49253318/v1
Stein, G. S. (2024) · Cambridge University Press eBooks · doi:10.1017/9781911623861.030
Chapter 53. Treatment of Schizophrenia
Brunette, M. F., Ballon, J. S., Gnanasegaram, S. A., Kalinowski, A., Keller, W. R., Reed, J. D., & Noordsy, D. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as53
Idées et conduites suicidaires: Une dimension transdiagnostique pour une psychiatrie de précision
Lengvenytė, A., Olié, É., Leboyer, M., & Courtet, P. (2025) · médecine/sciences · doi:10.1051/medsci/2025066
Methodologies Employed in Economic Evaluation of Suicide Prevention Interventions: A Scoping Review
Ryen, L., & Vimefall, E. (2025) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-025-01481-8
Menard, M.-L., Auby, P., Cruzel, C., Cohen, D., Bonnot, O., Askenazy-Gittard, F., & Thümmler, S. (2022) · Figshare · doi:10.6084/m9.figshare.21547205
Yin, Y., Lin, C., Wei, L., Tong, J., Huang, J., Tian, B., Tan, S., Wang, Z., Yang, F., Tong, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26027599
Bokhari, S. A., Elnoor, M., Javaid, S. F., & Alnor, M. A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1808636
“This proportion is substantially lower than reported utilisation in Finland (22.0% of schizophrenia patients) (Taipale et al., 2021), China (31.9”
InfluentialGranat, M., McCall, W. V., & Miller, B. J. (2026) · Crisis · doi:10.1027/0227-5910/a001068
Benzodiazépines et risque suicidaire
Tournier, M. (2025) · Elsevier eBooks · doi:10.1016/b978-2-294-78794-2.00042-7
Bornheimer, L. A., DeVylder, J., Smith, M. J., Brdar, N. M., Campbell, M., Kelter, A. N., Anderson, E., Xu, S., Hoener, K., Florence, T., et al. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.08.001 · Cited by 1
Suicide in schizophrenia: a comprehensive narrative review of risk factors and prevention strategies
Touhami, Y. O. H., Layoussifi, E., & Benjelloun, R. (2026) · Middle East Current Psychiatry · doi:10.1186/s43045-026-00672-9
“In long-term studies, clozapine has demonstrated a significant superiority over other antipsychotics, with suicide behavior reductions ranging from 70% to 85% [126, 127].”
Suizidales Erleben und Verhalten: Klinische Einordnung, Prävention und Behandlung
Kersting, X. A. K., & Lewitzka, U. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2699-3482
Scholle, O. H. F., Taipale, H. T., Dörks, M., Ohmes, J., Aagaard, L., Aizberg, O., Al‐Huseini, S., Alnor, M. A., Bajraktarov, S., Bertolini, P., et al. (2026) · medRxiv · doi:10.64898/2026.09.17.26363131
Self-citation
Metadata
- Authors
- Taipale, H., Lähteenvuo, M., Tanskanen, A., Mittendorfer-Rutz, E., & Tiihonen, J.
- Affiliations
- University of Eastern Finland (FI)
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- Corresponding author
- Taipale, Heidi
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-15
- Volume
- 47
- Issue
- 1
- Pages
- 23-30
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC7824993
- OpenAlex
- W3028392069
- Cited by
- 85
- References
- 37
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 16 · 2023: 11 · 2022: 14 · 2021: 11 · 2020: 2
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Schizophrenia Bulletin (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Finnish Ministry of Social Affairs and Health
- Academy of Finland (315969, 320107)
- Finnish Medical Foundation
- Emil Aaltonen Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs
- MeSH terms
- Suicide, Completed, Adolescent, Adult, Clozapine, Female, Finland, Humans, Male, Middle Aged, Registries, Risk, Schizophrenia, Suicide, Attempted, Sweden, Antipsychotic Agents, Cohort Studies, Young Adult, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.